Mastocytosis is a disease of disordered mast cell proliferation which affects all ages. Clinical presentation and prognosis depend on the category of disease, which ranges between a benign and self-limited skin disease to more aggressive forms associated with hematologic disorders. The most common sites of mast cell accumulation observed in patients with mastocytosis are skin and bone marrow. Skin lesions may eventually fade in some patients with longstanding disease. The pathologic basis of the mast cell collections in skin is not known; however it does not appear to be due to increased levels of mast cell growth factors in skin. In some cases, mastocytosis has an aggressive and ultimately fatal course. Thus, our efforts are directed to improving diagnosis and treatment; and to clarifying the etiology of this disease. Studies on c-kit and the relevance of activating mutations which we first identified (Asp816Val; Asp816Tyr) in patients with mastocytosis are continuing. Polymorphisms in other genes regulating mast cell growth and differentiation may influence the pathologic effects of c-kit mutations. Thus, a polymorphism in the IL4 receptor alpha chain has been identified to be associated with milder forms of mastocytosis. A successful approach to treatment for aggressive disease remains elusive. Currently available tyrosine kinase and Kit inhibitors do not appear to have a significant inhibitory effect on mutated Kit associated with mastocytosis. The efficacy of bone marrow transplantation in patients with severe bone marrow disease is currently being investigated.
| Akin, Cem; Valent, Peter; Metcalfe, Dean D (2010) Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 126:1099-104.e4 |
| Kulka, Marianna; Metcalfe, Dean D (2010) Isolation of tissue mast cells. Curr Protoc Immunol Chapter 7:Unit 7.25 |
| Lahortiga, Idoya; Akin, Cem; Cools, Jan et al. (2008) Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 93:49-56 |
| Simons, F E R; Frew, A J; Ansotegui, I J et al. (2008) Practical allergy (PRACTALL) report: risk assessment in anaphylaxis. Allergy 63:35-7 |
| Peavy, Richard D; Metcalfe, Dean D (2008) Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol 8:310-5 |
| Maric, Irina; Robyn, Jamie; Metcalfe, Dean D et al. (2007) KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 120:680-7 |
| Valent, P; Akin, C; Metcalfe, D D (2007) FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest 37:153-4 |
| Simons, F Estelle R; Frew, Anthony J; Ansotegui, Ignacio J et al. (2007) Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 120:S2-24 |
| Valent, P; Akin, C; Escribano, L et al. (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37:435-53 |
| Jensen, Bettina M; Metcalfe, Dean D; Gilfillan, Alasdair M (2007) Targeting kit activation: a potential therapeutic approach in the treatment of allergic inflammation. Inflamm Allergy Drug Targets 6:57-62 |
Showing the most recent 10 out of 65 publications
